%D9%83%D8%AB%D8%B1%D8%A9_%D8%A7%D9%84%D8%AD%D9%85%D8%B1_%D8%A7%D9%84%D8%AD%D9%82%D9%8A%D9%82%D9%8A%D8%A9EritremiyaPolicit%C3%A8mia_veraCategory:Polycythemia_veraPolycythaemia_veraPolycythemia_veraPolicitemia_veraEritrozitosi%D9%BE%D9%84%DB%8C_%D8%B3%DB%8C%D8%AA%D9%85%DB%8C_%D9%88%D8%B1%D8%A7Maladie_de_Vaquez%D7%A4%D7%95%D7%9C%D7%99%D7%A6%D7%99%D7%98%D7%9E%D7%99%D7%94Policitemija_veraPolicitemia_vera%E7%9C%9F%E6%80%A7%E5%A4%9A%E8%A1%80%E7%97%87%D0%92%D0%B0%D0%BA%D0%B5%D0%B7%D0%B0_%D0%B0%D1%83%D1%80%D1%83%D1%8B%EC%A7%84%EC%84%B1%EC%A0%81%ED%98%88%EA%B5%AC%EC%A6%9D%EA%B0%80%EC%A6%9D%D0%9F%D0%BE%D0%BB%D0%B8%D1%86%D0%B8%D1%82%D0%B5%D0%BC%D0%B8%D1%8FTikroji_policitemija%D0%9F%D0%BE%D0%BB%D0%B8%D1%86%D0%B8%D1%82%D0%B5%D0%BC%D0%B8%D1%98%D0%B0_%D0%A0%D1%83%D0%B1%D1%80%D0%B0_%D0%92%D0%B5%D1%80%D0%B0Polycythaemia_veraCzerwienica_prawdziwaPolicitemia_vera%D0%98%D1%81%D1%82%D0%B8%D0%BD%D0%BD%D0%B0%D1%8F_%D0%BF%D0%BE%D0%BB%D0%B8%D1%86%D0%B8%D1%82%D0%B5%D0%BC%D0%B8%D1%8FPolycytemia_veraPrawo_czerwjy%C5%84ica%E0%B9%82%E0%B8%9E%E0%B8%A5%E0%B8%B5%E0%B9%84%E0%B8%8B%E0%B8%97%E0%B8%B5%E0%B9%80%E0%B8%A1%E0%B8%B5%E0%B8%A2_%E0%B9%80%E0%B8%A7%E0%B8%AD%E0%B8%A3%E0%B8%B2%D0%A1%D0%BF%D1%80%D0%B0%D0%B2%D0%B6%D0%BD%D1%8F_%D0%BF%D0%BE%D0%BB%D1%96%D1%86%D0%B8%D1%82%D0%B5%D0%BC%D1%96%D1%8FQ948318
about
Phyllis GeorgeAzacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesDose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic SyndromeSafety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) PatientsMomelotinib Versus Ruxolitinib in Subjects With MyelofibrosisOpen Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisA Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential ThrombocythaemiaSecondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK InhibitorFludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerTacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerA Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic MyelofibrosisPD-1 Inhibition in Advanced Myeloproliferative NeoplasmsStudy of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative NeoplasmsSafety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MFAlternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisSafety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisStudy With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaRuxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosisLBH589 (Panobinostat) for the Treatment of MyelofibrosisOpen Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia VeraExtension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 InhibitorsExtended Access of Momelotinib in Adults With MyelofibrosisInfection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaMPN-RC 118 AVID200 in MyelofibrosisThe NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility PhaseAn Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibKRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia VeraAssess the Safety, Tolerability Oral PU-H71 in Subjects Taking RuxolitinibAnti-TGF-beta Therapy in Patients With MyelofibrosisStudy of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)Treatment of Polycythemia Vera With GleevecTrial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia VeraA Study in Myeloproliferative Disorders
P1050
P509
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibRationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisMPNs as Inflammatory Diseases: The Evidence, Consequences, and PerspectivesBlast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsImpact of Inflammation on Myeloproliferative Neoplasm Symptom DevelopmentThe treatment of polycythaemia vera: an update in the JAK2 eraCurrent and future treatment options for polycythemia vera.Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.Coexistence of chronic lymphocytic leukemia and polycythemia vera: a case report and review of the literature.Polycythemia vera treatment algorithm 2018.
P921
Q3901730-6f75a590-43e0-a4cf-6b4f-1528c41be72eQ61894499-36651B89-B771-49DE-BBFD-C6C04E0CA2BBQ61908774-8F9E7446-C230-45ED-907B-E75F54728DE5Q61924544-2B0E842D-A0C0-4D8A-921B-D93F535B28B3Q61969415-F04D7646-2A2A-45D5-B647-BEA20DEEBA6AQ61975323-C0BAF024-9C2D-4A22-B3CC-00CF1828DA8CQ61975403-CF8D3D13-D0C6-454B-979F-F9471F043D01Q61979326-395D03B0-64A2-4A5F-9493-EF01D6262A26Q61980959-EBF5DAA1-A2C4-4397-9D47-5735BBB157CDQ62034506-ED57613E-CACC-4487-A5F4-E21712CBC100Q62062253-8F979B1F-E447-456D-B536-7913FA2CDD2EQ62105038-0F2007E6-F0C2-416F-A0B4-DBB91F4C7678Q62110098-73F50073-AB47-4469-9CF2-1701F53581B2Q63062220-14BB83A2-053B-4680-ADAB-F0BC6FE68D37Q63229537-5719440A-DE24-4E8E-BDA2-475D89285C77Q63320463-9E9B7C63-1962-4DBA-84A1-0E6EE3F241C9Q63321625-3DE1610D-DFD5-4F6E-8940-31A66D18546EQ63321638-235A594A-029C-4649-810A-38AE2C7B2B99Q63321780-9484050D-8728-4C9F-A773-01DD0D8CE302Q63322214-DC5D0014-472A-4E22-A78B-738298058A9CQ63335474-4F015282-AD96-41CF-8460-04007E04774AQ63338573-8794B4F1-BB4F-4E9B-BAA1-0151A8EE5577Q63340079-5B9EDFFD-5761-4E93-A9D9-33D14AD4A616Q63340642-5E6020F5-A6A5-4E63-9E79-1AEB6BC86F92Q63393521-0BA61CD4-9CC2-47FE-A52B-84295CBEABE7Q63401017-CFF03587-2FB8-470B-9989-18C6D234E270Q63572918-C8FFEB2E-9331-436E-AE5B-1ABD5C98B7A9Q63577998-E4398F61-BA86-4367-B49A-BFF64283BD21Q63580663-E874AD4B-942C-49CC-84D8-EDF0C84509E8Q63587655-795236DC-3216-40F0-A872-1E8418637195Q63594153-22EBD577-482A-4668-A857-A7B4F2EA55E2Q63599122-F32761F0-E347-480D-B757-652381D07D76Q63805315-8C2F910E-9ADC-4DB0-8185-F7B88C3D55DFQ63814063-B0B8CEFF-0643-4FC5-9107-FBDD7C385C56Q63816158-7C48B0A4-17E2-4B27-A9A6-B6CACB74B0D4Q63817590-27B80599-001D-4DC7-BCD2-0D7D95FCD196Q63817596-3A4FB0CC-2A44-4819-A82C-D380F12CAF82Q63830186-D0ECB09F-E1B9-4C18-BCD1-5EA96E7536FBQ63834308-6FDEDBED-7F81-4ED7-AFEF-E90B752F0172Q63834477-B42AA234-1FE9-4CA4-A359-82D5177BDE4C
P1050
Q15211075-D0696413-A364-4A46-AD29-6A1CA1CD2E8FQ15366704-5D49F8CD-2345-4147-A94C-F580B74B70D0Q15366704-E6F9742B-C222-45C0-9252-A8877FED69EBQ212272-42077C38-2C92-4D5D-AB9A-11AF6F040C51Q348922-03AF2C81-34F0-411F-8B52-35E90CC2A8BAQ408163-434C6226-C1A5-41E2-B4E5-92B3AF1D96FCQ420056-690F97F8-CF5A-47F4-8E52-8F4CF3DD9396Q7383611-BC59D682-3BDB-48B9-A38A-138FB98357D8
P2175
description
Blutkrankheit
@de
human disease
@en
policitemia vera
@it
مرض يصيب الإنسان
@ar
name
Eritremiya
@az
Eritrocitozė
@lt
Eritrozitosi
@eu
Polycythaemia vera
@de
Polycythaemia vera
@nl
Polycythemia vera
@hi
Polycythemia vera
@zh-hant
Prawo czerwjyńica
@szl
Vakeza awrwı
@kk-latn
czerwienica prawdziwa
@pl
type
label
Eritremiya
@az
Eritrocitozė
@lt
Eritrozitosi
@eu
Polycythaemia vera
@de
Polycythaemia vera
@nl
Polycythemia vera
@hi
Polycythemia vera
@zh-hant
Prawo czerwjyńica
@szl
Vakeza awrwı
@kk-latn
czerwienica prawdziwa
@pl
altLabel
Acquired primary erythrocytosis
@en
Morbus Vaquez-Osler
@de
Osler-Vaquez disease
@en
Osler-Vaquez syndrome
@en
POLYCYTHEMIA VERA; PV
@en
PV
@en
Polizitemia
@eu
Polycytemia vera
@nl
Polycythaemia vera rubra
@pl
Polycythaemia vera
@pl
prefLabel
Eritremiya
@az
Eritrocitozė
@lt
Eritrozitosi
@eu
Polycythaemia vera
@de
Polycythaemia vera
@nl
Polycythemia vera
@hi
Polycythemia vera
@zh-hant
Prawo czerwjyńica
@szl
Vakeza awrwı
@kk-latn
czerwienica prawdziwa
@pl
P2176
P279
P2888
P672
P486
P6366
P646
P1375
P1417
science/polycythemia-vera